Erratum: Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial (The Lancet (2017) 389(10074) (1103–1113)(S0140673617300600)(10.1016/S0140-6736(17)30060-0));Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial

The Lancet

Volumn 389, Issue 10074, 2017, Pages 1103-1113

  Németh, György ^a   Laszlovszky, István ^a   Czobor, Pál ^b   Szalai, Erzsébet ^a   Szatmári, Balázs ^a   Harsányi, Judit ^a   Barabássy, Ágota ^a   Debelle, Marc ^a   Durgam, Suresh ^c   Bitter, István ^b   Marder, Stephen ^d   Fleischhacker, W Wolfgang ^e  

^a GEDEON RICHTER LTD   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c FOREST RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTIPARKINSON AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BIPERIDEN; CARIPRAZINE; CHOLESTEROL; CREATINE KINASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROPRANOLOL; RISPERIDONE; TRIACYLGLYCEROL; TRIHEXYPHENIDYL; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE;

ADULT; AKATHISIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANXIETY DISORDER; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BODY MASS; BRAIN TUMOR; BULGARIA; CARCINOID; CHOLESTEROL BLOOD LEVEL; CHRONOPHARMACOLOGY; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL (TOPIC); COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CROATIA; CZECH REPUBLIC; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; ECG ABNORMALITY; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; FOLLOW UP; FRANCE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HUNGARY; HYPERTENSION; INFORMATION SYSTEM; INSOMNIA; INTENTION TO TREAT ANALYSIS; INTERACTIVE WEB RESPONSE SYSTEM; INTRAOCULAR PRESSURE ABNORMALITY; LUNG TUMOR; MAJOR CLINICAL STUDY; MALE; MASS COMMUNICATION; MEDIASTINUM METASTASIS; MENTAL PATIENT; METABOLIC PARAMETERS; MONOTHERAPY; MULTICENTER STUDY; MUSCLE RIGIDITY; NAUSEA; NEGATIVE SYNDROME; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PHASE 3 CLINICAL TRIAL; POLAND; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PRIVATE HOSPITAL; PROSPECTIVE STUDY; PSYCHOPHARMACOTHERAPY; PULSE RATE; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; RHINOPHARYNGITIS; ROMANIA; RUSSIAN FEDERATION; SCHIZOPHRENIA; SERBIA; SIDE EFFECT; SOMNOLENCE; SPAIN; SUICIDAL IDEATION; SUICIDE ATTEMPT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; UKRAINE; UNIVERSITY HOSPITAL; VISUAL DISORDER; VITAL SIGN; WAIST CIRCUMFERENCE; WEIGHT CHANGE; BEHAVIOR; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; ETIOLOGY; MIDDLE AGED; PSYCHOLOGY;

ADULT; ANTIPSYCHOTIC AGENTS; BEHAVIORAL SYMPTOMS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 85011601251     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)30646-3     Document Type: Erratum

References (31)

1. 1 Buchanan, RW, Persistent negative symptoms in schizophrenia: an overview. Schizophr Bull 33 (2007), 1013–1022.
2. 2 Arango, C, Garibaldi, G, Marder, SR, Pharmacological approaches to treating negative symptoms: a review of clinical trials. Schizophr Res 150 (2013), 346–352.
3. 3 Kiss, B, Horváth, A, Némethy, Z, et al. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther 333 (2010), 328–340.
4. 4 Kiss, B, Horti, F, Bobok, A, Cariprazine, a D3/D2 dopamine receptor partial agonist antipsychotic, displays greater D3 receptor occupancy in vivo compared with other antipsychotics. Schizophr Res, 136(suppl 1), 2012, S190 (abstr).
5. 5 Girgis, RR, Slifstein, M, D'Souza, DC, et al. Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [11C]-(+)-PHNO. Psychopharmacology 233 (2016), 3503–3512.
6. 6 Cho, DI, Zheng, M, Kim, KM, Current perspectives on the selective regulation of dopamine D(2) and D(3) receptors. Arch Pharm Res 33 (2010), 1521–1538.
7. 7 Gyertyán, I, Sághy, K, Laszy, J, et al. Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15. Naunyn Schmiedebergs Arch Pharmacol 378 (2008), 529–539.
8. 8 Joyce, JN, Millan, MJ, Dopamine D3 receptor antagonists as therapeutic agents. Drug Discov Today 10 (2005), 917–925.
9. 9 Gyertyán, I, Kiss, B, Sághy, K, et al. Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents. Neurochem Int 59 (2011), 925–935.
10. 10 Neill, JC, Grayson, B, Kiss, B, Gyertyán, I, Ferguson, P, Adham, N, Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology. Eur Neuropsychopharmacol 26 (2016), 3–14.
11. 11 Papp, M, Gruca, P, Lason-Tyburkiewicz, M, Adham, N, Kiss, B, Gyertyán, I, Attenuation of anhedonia by cariprazine in the chronic mild stress model of depression. Behav Pharmacol 25 (2014), 567–574.
12. 12 Zimnisky, R, Chang, G, Gyertyán, I, Kiss, B, Adham, N, Schmauss, C, Cariprazine, a dopamine D(3)-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse. Psychopharmacology (Berl) 226 (2013), 91–100.
13. 13 Debelle, M, Faradzs-zade, S, Szatmári, B, et al. Cariprazine in negative symptoms of schizophrenia: post hoc analyses of a fixed-dose, placebo and active controlled trial. Eur Neuropsychopharm, 24(suppl 1), 2014, S534 (abstr).
14. 14 Debelle, M, Faradzs-zade, S, Szatmári, B, et al. Cariprazine in negative symptoms of schizophrenia: post-hoc analyses of a fixed-dose phase III, randomized, double-blind, placebo- and active-controlled trial. Eur Psychiatry, 30(suppl), 2015, 242 (abstr).
15. 15 Marder, SR, Daniel, DG, Alphs, L, Awad, AG, Keefe, RS, Methodological issues in negative symptom trials. Schizophr Bull 37 (2011), 250–254.
16. 16 Mohr, PE, Cheng, CM, Claxton, K, et al. The heterogeneity of schizophrenia in disease states. Schizophr Res 71 (2004), 83–95.
17. 17 Milev, P, Ho, BC, Arndt, S, Andreasen, NC, Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry 162 (2005), 495–506.
18. 18 Brain, C, Allerby, K, Sameby, B, et al. Drug attitude and other predictors of medication adherence in schizophrenia: 12 months of electronic monitoring (MEMS®) in the Swedish COAST-study. Eur Neuropsychopharmacol 23 (2013), 1754–1762.
19. 19 European Medicines Agency. Guideline on clinical investigation of medicinal products, including depot preparation in the treatment of schizophrenia. 20 September 2012; EMA/CHMP/40072/2010 Rev. 1. Committee for Medicinal Products for Human Use (CHMP). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/10/WC500133437.pdf (accessed Dec 4, 2015).
20. 20 Laughren, T, Levin, R, Food and Drug Administration commentary on methodological issues in negative symptom trials. Schizophr Bull 37 (2011), 255–256.
21. 21 Moller, HJ, Czobor, P, Pharmacological treatment of negative symptoms in schizophrenia. Eur Arch Psychiatry Clin Neurosci 265 (2015), 567–578.
22. 22 Danion, JM, Rein, W, Fleurot, O, Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group. Am J Psychiatry 156 (1999), 610–616.
23. 23 Loo, H, Poirier-Littre, MF, Theron, M, Rein, W, Fleurot, O, Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br J Psychiatry 170 (1997), 18–22.
24. 24 Boyer, P, Lecrubier, Y, Puech, AJ, Dewailly, J, Aubin, F, Treatment of negative symptoms in schizophrenia with amisulpride. Br J Psychiatry 166 (1995), 68–72.
25. 25 Paillere-Martinot, ML, Lecrubier, Y, Martinot, JL, Aubin, F, Improvement of some schizophrenic deficit symptoms with low doses of amisulpride. Am J Psychiatry 152 (1995), 130–134.
26. 26 Lecrubier, Y, Quintin, P, Bouhassira, M, Perrin, E, Lancrenon, S, The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial. Acta Psychiatr Scand 114 (2006), 319–327.
27. 27 Olie, JP, Spina, E, Murray, S, Yang, R, Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study. Int Clin Psychopharmacol 21 (2006), 143–151.
28. 28 Leucht, S, Corves, C, Arbter, D, Engel, RR, Li, C, Davis, JM, Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373 (2009), 31–41.
29. 29 Buchanan, RW, Panagides, J, Zhao, J, et al. Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia. J Clin Psychopharmacol 32 (2012), 36–45.
30. 30 Lindenmayer, JP, Khan, A, Iskander, A, Abad, MT, Parker, B, A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia. J Clin Psychiatry 68 (2007), 368–379.
31. 31 Marder, SR, Alphs, L, Anghelescu, IG, et al. Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia. Schizophr Res 150 (2013), 328–333.